Serum estrogens and estrogen metabolites and endometrial cancer risk among postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 7, 2016, Pages 1081-1089

  Brinton, Louise A ^a   Trabert, Britton ^a   Anderson, Garnet L ^b   Falk, Roni T ^a   Felix, Ashley S ^a,c   Fuhrman, Barbara J ^d   Gass, Margery L ^e   Kuller, Lewis H ^f   Pfeiffer, Ruth M ^a   Rohan, Thomas E ^g   Strickler, Howard D ^g   Xu, Xia ^h   Wentzensen, Nicolas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e University of Pittsburgh ^*  (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 4 HYDROXYESTRONE; 4 METHOXYESTRADIOL; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; ESTROGEN BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; OBESITY; OBSERVATIONAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; TANDEM MASS SPECTROMETRY; WOMEN'S HEALTH; BLOOD; CARCINOGENESIS; CLINICAL TRIAL; ENDOMETRIUM TUMOR; METABOLISM; MULTICENTER STUDY; ODDS RATIO; SELF REPORT; SENSITIVITY AND SPECIFICITY;

AGED; BIOMARKERS, TUMOR; CARCINOGENESIS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; RISK FACTORS; SELF REPORT; SENSITIVITY AND SPECIFICITY;

EID: 84977138823     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0225     Document Type: Article

References (40)

1. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 2002;11:1531-43
2. Brown SB, Hankinson SE. Endogenous estrogens and the risk of breast, endometrial, and ovarian cancers. Steroids 2015;99:8-10
3. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485-97
4. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 2008; 17:921-9
5. Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S, et al. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 2004;108:425-32
6. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, Koenig KL, Shore RE, Kim MY, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001;84:975-81
7. Ziegler RG, Fuhrman BJ, Moore SC, Matthews CE. Epidemiologic studies of estrogen metabolism and breast cancer. Steroids 2015;99:67-75
8. Bradlow HL, Sepkovic DW, Klug T, Osborne MP. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids 1998;63:406-13
9. Fishman J, Schneider J, Hershcope RJ, Bradlow HL. Increased estrogen-16 alpha-hydroxylase activity in women with breast and endometrial cancer. J Steroid Biochem 1984;20:1077-81
10. Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006;1766:63-78
11. Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey JVJr, Cauley JA, et al. Estrogen metabolism and breast cancer risk among postmenopausalwomen: a casecohort study within B-FIT. Carcinogenesis 2014;35:346-55
12. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, et al. Estrogenmetabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012;104:326-39
13. Zeleniuch-Jacquotte A, Shore RE, Afanasyeva Y, Lukanova A, Sieri S, Koenig KL, et al. Postmenopausal circulating levels of 2-and 16alpha-hydroxyestrone and risk of endometrial cancer. Br J Cancer 2011;105:1458-64
14. Dallal CM, Lacey JV Jr, Pfeiffer RM, Bauer DC, Falk RT, Buist DS, et al. Estrogen metabolism and risk of postmenopausal endometrial and ovarian cancer: the B approximately FIT Cohort. Horm Cancer 2016; 7:49-64
15. Audet-Walsh E, Lepine J, Gregoire J, Plante M, Caron P, Tetu B, et al. Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics. J Clin Endocrinol Metab 2011;96:E330-9
16. Zhao H, Jiang Y, Liu Y, Yun C, Li L. Endogenous estrogen metabolites as biomarkers for endometrial cancer via a novel method of liquid chromatography-mass spectrometry with hollow fiber liquid-phase microextraction. Horm Metab Res 2015;47:158-64
17. Brinton LA, Felix AS,McMeekin DS, Creasman WT, Sherman ME, Mutch D, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 2013;129:277-84
18. Setiawan VW, Yang HP, PikeMC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 2013;31:2607-18
19. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials 1998;19:61-109
20. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol 2003;13: S107-21
21. Trabert B, Brinton LA, Anderson GL, Pfeiffer RM, Falk RT, Strickler HD, et al. Circulating estrogens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study. Cancer Epidemiol Biomarkers Prev. 2016 Feb 5. [Epub ahead of print]
22. Xu X, Roman JM, Issaq HJ, Keefer LK, Veenstra TD, Ziegler RG. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography-tandemmass spectrometry. Anal Chem 2007;79:7813-21
23. Loud JT. Circulating estrogens and estrogens within the breast among postmenopausal BRCA1/2 mutation carriers. Breast Cancer Res Treat 2014;148:691-2
24. Newbold RR, Liehr JG. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 2000;60:235-7
25. Reddy VV, Hanjani P, Rajan R. Synthesis of catechol estrogens by human uterus and leiomyoma. Steroids 1981;37:195-203
26. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27
27. Takahashi M, Shimomoto T, Miyajima K, Yoshida M, Katashima S, Uematsu F, et al. Effects of estrogens and metabolites on endometrial carcinogenesis in young adult mice initiated with N-ethyl-N0-nitro-Nnitrosoguanidine. Cancer Lett 2004;211:1-9
28. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol 2012;13:476-86
29. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2013;132:417-26
30. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987;45:277-82
31. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 2003;95:1218-26
32. Rinaldi S, Key TJ, Peeters PH, Lahmann PH, Lukanova A, Dossus L, et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer 2006;118:2832-9
33. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7
34. Felix AS, Weissfeld JL, Stone RA, Bowser R, Chivukula M, Edwards RP, et al. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control 2010;21:1851-6
35. McCullough ML, Patel AV, Patel R, Rodriguez C, Feigelson HS, Bandera EV, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008;17: 73-9
36. Yang HP, Wentzensen N, Trabert B, Gierach GL, Felix AS, Gunter MJ, et al. Endometrial cancer risk factors by 2 main histologic subtypes: the NIH-AARP Diet and Health Study. Am J Epidemiol 2013;177: 142-51
37. Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML, et al. Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 1997;10:963-8
38. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295-308
39. Zannoni GF, Vellone VG, Arena V, Prisco MG, Scambia G, Carbone A, et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch 2010;457:27-34
40. Stanczyk FZ, Mathews BW, Sherman ME. Relationships of sex steroid hormone levels in benign and cancerous breast tissue and blood: a critical appraisal of current science. Steroids 2015;99:91-102